A Study of Efimosfermin Alfa in Adults With Hepatic Impairment — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment — Stella

Recruiting

Back to Non-alcoholic Fatty Liver Disease trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

GSK Investigational Site, Rialto, California

GSK Investigational Site, Tampa, Florida

GSK Investigational Site, San Antonio, Texas

Key details

Phase

Early testing

Sponsor

GlaxoSmithKline

Enrollment target

~32 participants

Started

March 2026

Primary completion

October 2027

Age range

18 Years – 70 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov